1. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. London: NICE; 2013.
http://publications.nice.org.uk/pmg9
. Accessed 23 Aug 17.
2. Armstrong N, Grimm S, Ramaekers BLT, Pouwels X, Lang S, Fayter D, et al. Nivolumab for treating metastatic or unresectable urothelial cancer. York: Kleijnen Systematic Reviews Ltd; 2017.
3. National Institute for Health and Care Excellence. Nivolumab for treating metastatic or unresectable urothelial cancer after platinum-based chemotherapy [ID995].
https://www.nice.org.uk/guidance/indevelopment/gid-ta10163
. Accessed 15 Jun 2018.
4. Bristol-Myers Squibb Pharmaceuticals Ltd. Nivolumab for treating metastatic or unresectable urothelial cancer after platinum-based chemotherapy [ID995]. Document B: Company evidence submission. Submission to National Institute of Health and Clinical Excellence. Single technology appraisal (STA): Bristol-Myers Squibb Pharmaceuticals Ltd, 2017. 143p.
https://www.nice.org.uk/guidance/ta530/documents/committee-papers
. Accessed 10 Jul 2018.
5. Pasin E, Josephson DY, Mitra AP, Cote RJ, Stein JP. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol. 2008;10(1):31–43.